In acute myeloid leukemia, especially in the M2 subtype, the t (8;21) (q22;q22) translocation is one of the most frequent karyotypic abnormalities. The translocation produces a chimeric gene made up of the 5'-region of the RUNX1 gene fused to the 3'-region of this gene.

Mar 30, 2025 · RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) is a Protein Coding gene. Diseases associated with RUNX1T1 include Acute Myeloid Leukemia With T (8;21) (Q22;Q22) Translocation and Hematologic Cancer. Among its related pathways are Wnt/beta-catenin signaling pathway in leukemia and Acute myeloid leukemia.

Jul 28, 2022 · RUNX1T1 (Runt-related transcription factor 1, translocated to 1), a myeloid translocation gene (MTG) family member, is usually investigated as part of the fusion protein RUNX1-RUNX1T1 for its role in acute myeloid leukemia.

Jan 22, 2021 · The fusion oncogene RUNX1/RUNX1T1 encodes an aberrant transcription factor, which plays a key role in the initiation and maintenance of acute myeloid leukemia.

RUNX1/RUNX1T1 is the most common fusion gene found in acute myeloid leukemia. Seminal contributions by many different research groups have revealed a complex regulatory network promoting leukemic self-renewal and propagation.

Feb 19, 2025 · RUNX1T1, a potential prognostic marker in breast cancer, is co-ordinately expressed with ERalpha, and regulated by estrogen receptor signalling in breast cancer cells. AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms.

Mar 7, 2019 · Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.

The RUNX1T1 gene provides instructions for making a protein commonly referred to as ETO, which helps regulate the activity of genes. Learn about this gene and related health conditions.

Jan 14, 2020 · In this review, we present an up-to-date overview of the molecular features of this subtype of AML, focusing on the disruption caused by RUNX1-RUNX1T1 fusion, the cooperating mutations that have been uncovered, the activation of oncogenes and signaling pathways, and the role of microRNAs (miRs).

RUNX1/RUNX1T1 regulates gene expression at multiple levels. The fusion protein can dysregulate transcription by binding to promoter, enhancer, or silencer elements. RUNX1/RUNX1T1 also affects the ratios of RNA isoforms by regulating alternative promotor activity and affecting RNA splicing.